Prime Minister Keir Starmer’s government is reportedly poised to accept higher NHS drug prices as part of a broader effort to head off pressure from U.S. pharmaceutical policy demands. The move comes amid threats by President Trump of punitive tariffs on branded medicines unless companies lower U.S. prices or shift production to American soil. Late this week sources said the UK would allow price increases for certain medications to offset revenue losses that drugmakers might face under Trump’s pricing demands. That shift signals a departure from long‑standing UK practice of aggressively negotiating down drug costs for the NHS. The background to the move is a sweeping U.S. tariff threat. Starting October 1, the U.S. intends to impose 100 percent tariffs on branded pharmaceutical imports from firms that have not established manufacturing in the U.S. Britain is currently not shielded by existing trade agreements that cap tariffs on EU exporters because its pharma tariff rules remain unresolved.  Officials in London say they are pressing the U.S. for a more favourable outcome. Earlier tension had already surfaced between government and industry. The current UK drug pricing framework faces growing dissent from pharmaceutical firms frustrated by rebate schemes and caps.  In August, Eli Lilly announced a 170 percent hike in the UK list price for its weight‑loss and diabetes drug Mounjaro, triggering alarm about the sustainability of low prices. At the same time, major firms including Merck and AstraZeneca have paused planned investments in UK operations due to what they describe as deteriorating returns under current pricing rules. In response government officials have begun hinting at reform. The science minister has publicly suggested reconsideration of how drug value is assessed, including revisiting metrics that inform NHS cost‑effectiveness evaluations. A fund has also been launched to attract large life sciences projects. Despite these gestures, the government has not officially confirmed that it will pay more across the board. A spokesperson emphasised that the U.K. remains in “constructive dialogue” with both the U.S. and industry, stressing that any adjustments must balance innovation with value for taxpayers. Even so, the reported willingness to raise NHS drug prices marks a stark pivot in posture toward pharmaceutical companies. That posture has been spurred in part by growing fear of the impact of U.S. demands. Some analysts warn that unless the UK concedes, companies may deprioritise the British market, delay new drug launches, or reallocate R&D investment elsewhere. The challenge for Starmer’s government is to navigate a path that avoids shipping costs upward for taxpayers or patients while keeping the UK competitive in life sciences....